First study of MIL97 for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests MIL97, a new treatment, in adults with advanced solid cancers that have come back or cannot be removed. The goal is to find a safe dose and see how the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your solid tumor cancer is advanced (metastatic or cannot be surgically removed) and has come back or did not respond to prior treatment.
- You have at least one measurable tumor outside the brain that can be tracked, and/or a “checkable” tumor lesion.
- Your general condition is fairly good (ECOG 0 or 1), and your expected survival is at least 3 months.
- Your blood and organ tests are strong enough, checked within 7 days before starting.
- You can sign informed consent and follow study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new antibody drug called MIL95 in people with cancers that have come back or did not respond to prior treatment. It focuses on checking safety and early signs of how well the treatment may work.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This early-stage study tests KM257, a new cancer treatment, in people with advanced solid tumors that are HER2-positive or HER2-expressing. The goal is to see how well it can work and how safe it is.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced or Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.